Xiangying Zhu

Title: Innovations of Xiangying Zhu in Tumor Treatment

Introduction

Xiangying Zhu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the area of tumor treatment. With a total of 2 patents, his work focuses on the applications of specific human genes in combating cancer.

Latest Patents

Xiangying Zhu's latest patents include groundbreaking research on the human ZFX gene. The first patent discloses the uses of the human ZFX gene and associated drugs. This invention highlights the potential of the ZFX gene in tumor treatment, diagnosis, and drug preparation. It also introduces small interfering RNA (siRNA) and nucleic acids that can specifically inhibit the expression of the human ZFX gene. The use of lentiviruses in this context is particularly noteworthy, as they can efficiently infect target cells, inhibit ZFX expression, and promote tumor apoptosis.

The second patent focuses on the human NLK gene and its associated drugs. This invention outlines the use of the NLK gene for tumor treatment, diagnosis, and drug preparation. It constructs an isolated molecule that attenuates the expression of the NLK gene in tumor cells. The NLK interference lentivirus is also disclosed, which can effectively infect target cells and inhibit the growth of tumor cells, showcasing its significance in cancer therapy.

Career Highlights

Xiangying Zhu is currently associated with Shanghai Genechem Co., Ltd., where he continues to advance his research in gene therapy and cancer treatment. His innovative approaches have positioned him as a key figure in the biotechnology sector.

Collaborations

Xiangying Zhu collaborates with notable colleagues, including Yueqiong Cao and Haixiong Han. Their combined expertise enhances the research and development efforts at Shanghai Genechem Co., Ltd.

Conclusion

Xiangying Zhu's contributions to the field of biotechnology, particularly in tumor treatment through his innovative patents, demonstrate his commitment to advancing medical science. His work has the potential to significantly impact cancer therapy and improve patient outcomes.